BERRY GLOBAL, a leading provider of innovative packaging and engineered products, and PYLOTE, a key player in the industrial mineral chemistry, announce a strategic commercial partnership to address the needs of innovative antimicrobial packaging solutions which are more sustainable, cleaner and safer for patients and consumers.

Following successful joint evaluations, BERRY GLOBAL and PYLOTE are launching a first-to-market offering with a unique multidose ophthalmic dropper combining high barrier with antimicrobial protection properties.

This new offer combines PYLOTE’s mineral breakthrough innovation that helps protect patients/users from the risk of microbial infections with BERRY GLOBAL’s expertise in design of sustainable healthcare packaging.

Berry and Pylote introduce a new ophthalmic multidose dropper to help avoid the risk of microbial infections for patients.

Thanks to the mineral antimicrobial technology of PYLOTE, this new multidose ophthalmic dropper is notably proven effective against Adenovirus type 3 Virus (conjunctivitis), Escherichia Coli and Staphylococcus aureus bacteria.

This common breakthrough product offers the market with competitive advantages in terms of patients’ protection, time-to-market and sustainability, while offering other benefits:

• Proven and certified mineral antimicrobial protection of dropper tip where over 85% of the contamination of the drops is found according to a clinical study

• Allows patients to have hygienic applications for every use with a multidose dropper

• Reduces the amount of plastic waste by 16 times for one month treatment compared to monodose solutions

• No change in patient treatment methods

• Fully compliant, stable and biocompatible while certified non-irritant and non-cytotoxic technology (ISO10993:2010)

• No modifications required to packaging design or existing manufacturing/filling processes

Mandy McCain, Head of BERRY GLOBAL Healthcare Division, commented, “This new partnership is incredibly exciting for us in the world of Ophthalmics to further protect patients, provide them comfort while dispensing the drug and supporting further adherence to their treatments."

Loïc Marchin, CEO of PYLOTE, stated, "Partnering with BERRY GLOBAL is a major step in our strategy to protect people with a shared sustainable commitment. BERRY GLOBAL offers a rich portfolio of healthcare devices for many applications. Our mineral technology, positively perceived by consumers, is an effective, robust and safe disruptive antimicrobial solution."

BERRY GLOBAL, a leading provider of innovative packaging and engineered products, and PYLOTE, a key player in the industrial mineral chemistry, announce a strategic commercial partnership to address the needs of innovative antimicrobial packaging solutions which are more sustainable, cleaner and safer for patients and consumers.

Following successful joint evaluations, BERRY GLOBAL and PYLOTE are launching a first-to-market offering with a unique multidose ophthalmic dropper combining high barrier with antimicrobial protection properties.

This new offer combines PYLOTE’s mineral breakthrough innovation that helps protect patients/users from the risk of microbial infections with BERRY GLOBAL’s expertise in design of sustainable healthcare packaging.

Berry and Pylote introduce a new ophthalmic multidose dropper to help avoid the risk of microbial infections for patients.

Thanks to the mineral antimicrobial technology of PYLOTE, this new multidose ophthalmic dropper is notably proven effective against Adenovirus type 3 Virus (conjunctivitis), Escherichia Coli and Staphylococcus aureus bacteria.

This common breakthrough product offers the market with competitive advantages in terms of patients’ protection, time-to-market and sustainability, while offering other benefits:

• Proven and certified mineral antimicrobial protection of dropper tip where over 85% of the contamination of the drops is found according to a clinical study

• Allows patients to have hygienic applications for every use with a multidose dropper

• Reduces the amount of plastic waste by 16 times for one month treatment compared to monodose solutions

• No change in patient treatment methods

• Fully compliant, stable and biocompatible while certified non-irritant and non-cytotoxic technology (ISO10993:2010)

• No modifications required to packaging design or existing manufacturing/filling processes

Mandy McCain, Head of BERRY GLOBAL Healthcare Division, commented, “This new partnership is incredibly exciting for us in the world of Ophthalmics to further protect patients, provide them comfort while dispensing the drug and supporting further adherence to their treatments."

Loïc Marchin, CEO of PYLOTE, stated, "Partnering with BERRY GLOBAL is a major step in our strategy to protect people with a shared sustainable commitment. BERRY GLOBAL offers a rich portfolio of healthcare devices for many applications. Our mineral technology, positively perceived by consumers, is an effective, robust and safe disruptive antimicrobial solution."